Clinical Labs CRO is a rules-based basket of 12 US-listed stocks — The top-rated US companies with the Clinical Labs CRO business model.. 17.8% backtested total return, -147.1% vs the S&P 500 since inception. Equal-weight, point-in-time, survivorship-corrected. Published for US investors. Not investment advice.
| Ticker | Company | Weight |
|---|---|---|
| MEDP | Medpace Holdings, Inc. | 8.3% |
| NEOG | Neogen Corporation | 8.3% |
| VCYT | Veracyte, Inc. | 8.3% |
| CRL | Charles River Laboratories International, Inc. | 8.3% |
| DGX | Quest Diagnostics Incorporated | 8.3% |
| LH | Labcorp Holdings Inc. | 8.3% |
| IQV | IQVIA Holdings Inc. | 8.3% |
| RGEN | Repligen Corporation | 8.3% |
| NTRA | Natera, Inc. | 8.3% |
| CDNA | CareDx, Inc | 8.3% |
| GH | Guardant Health, Inc. | 8.3% |
| CLDX | Celldex Therapeutics, Inc. | 8.3% |
Performance shown is backtested (hypothetical), not actual trades, benchmarked to the S&P 500 total return. Past performance does not guarantee future results. Signals is a publisher, not a broker or investment adviser. US users only.